Press releases

ten23 health® and BD partner to enable supply chain readiness of BD Libertas™ wearable injector as full-service solution

Basel, January 20, 2026 -  ten23 health today announced a manufacturing collaboration to support the commercialization of the BD Libertas™ wearable injector. The collaboration will offer biopharma companies supply chain readiness of a fully integrated, ready-to-use solution for the subcutaneous delivery of large-volume drugs, helping speed development and reduce risk in complex injectable programs.

Download Press Release

ten23 health® QC lab to support commercial product testing for U.S. customer following FDA approvals

Basel, December 9, 2025 -  ten23 health today announced that its recently established and Swissmedic approved Quality Control (QC) laboratories in both Basel and Visp, Switzerland, have been formally approved by the U.S. Food and Drug Administration (FDA). 

Download Press Release

ten23 health^® and Neumirna Therapeutics team up to develop RNA therapy for epilepsy

Basel, October 27, 2025 - The partnership aims to accelerate clinical translation of NMT.001, a microRNA-targeting RNA therapy for drug-resistant epilepsy.

Download Press Release

BD, ten23 health, and partners to demo full RFID syringe traceability at CPHI Frankfurt 

Basel, October 15, 2025 - New collaboration brings hands-on tour of unit-level traceability in injectable drug manufacturing to CPHI 2025 

Download Press Release

ten23 health joins the “Alliance for RTU” - an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing

Basel, June 30, 2025 – ten23 health has joined the „Alliance for RTU“, an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing.

Download Press Release

ten23 health establishes Advisory Board in collaboration with St. Gallen Symposium’s Young Leaders on Board

Basel, May 27, 2025 – ten23 health is proud to announce the establishment of its Advisory Board, bringing together leading global experts to confirm its commitment to a "Patients," "People," and "Planet" focused corporate social responsibility policy.

Download Press Release

ten23 health kickstarts new era with launch of industry-first robot-assisted pilot non-GMP sterile filling in its Basel facilities

Basel, May 12, 2025: Customers can now accelerate new product development with early access to non-GMP but clinically representative liquid and lyophilized batches. The pilot line is easy to access, reduces costs, and allows the use of material that would not be suitable for GMP processing.

Download Press Release

ten23 health proudly launches its GMP certified Quality Control (QC) & Testing services at its state-of-the-art Basel (BASE®) and Visp (VIVA2®) laboratories in Switzerland, celebrated with a grand opening in Basel featuring local dignitaries.

Basel, April 28, 2025 - ten23 health announces the launch of its quality control (QC) & testing services at both its Basel (BASE®) and Visp (VIVA2®) facilities

Download Press Release

ten23 health’s Fairstainability Impact Report 2024 confirms its position as a world leader in sustainable pharma manufacturing

Basel, 2 of April 2025: ten23 health is proud to announce a range of achievements and sustainability certifications, with the publication of its yearly Fairstainabilty Report.

Download Press Release

ten23 health and BD partner to advance efficiency and quality in aseptic manufacturing with RFID-enabled prefillable syringes

Basel, 7 of October 2024: ten23 health and BD (Becton, Dickinson and Company) (NYSE: BDX), today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Download Press Release

ten23 health hosts Grand Opening of its State-of-the-Art VIVA2® Sterile Manufacturing Facility in Visp, Switzerland

Visp, 24 of September 2024: The event marks a significant milestone in the company's growth, as the newly constructed VIVA2® facility is one of the most advanced and energy efficient of its kind

Download Press Release

ten23 health achieves its certification as a B Corporation, recognizing its commitment to social and environmental responsibility and sustainability

Basel, 16 of September 2024: ten23 health is proud to announce its official certification as a B Corporation (B Corp). ten23 health is the first biotech and sterile drug product CDMO in the pharmaceutical sector to achieve B Corp certification, which recognizes its dedication to meeting rigorous standards of social and environmental performance, accountability, and transparency.

Download Press Release

ten23 health® publishes its 2023 Fairstainability Impact Report and reports major progress on its Sustainability Goals

Basel, 22 of April 2024: ten23 health recognizes the importance of environmental stewardship, social responsibility, and its goal of driving positive change in the pharmaceutical and CDMO industry. The 2023 Fairstainability Impact Report transparently provides the status and progress towards achieving ten23´s sustainability goals.

Download Press Release

Download Report

ten23 health® and Ypsomed collaborate for the commercialization of patch injector

Burgdorf & Basel, 16 of April 2024. ten23 health® and Ypsomed, a leader in developing and manufacturing the new generation of patient-friendly injection and infusion systems, accounted today entering into partnership. The aim of this collaboration is to advance the commercialization of the YpsoDose wearable injector for the subcutaneous self-injection of large-volume doses. ten23’s drug development, filling and device assembly expertise will significantly contribute to the product offering.

Download

ten23 health® and SHL Medical announce a strategic partnership agreement for integrated services.

Basel, Switzerland, 25 of March 2024: ten23 health®, the Swiss contract development and manufacturing organization (CDMO) for sterile drugs, and SHL Medical, a world-leading provider of drug delivery devices, today announced their strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.

Download

ten23 health´s VIVA2 large-scale pre-filled syringe, cartridge, and vial aseptic Filling Line 2 in Switzerland GMP operational by end 2024

Basel, Switzerland, 18 of March 2024. ten23 health®, the Swiss contract development and manufacturing organization, today accounted that its VIVA2 aseptic large-scale pre-filled syringe (PFS), vial and cartridge Filling Line 2 will be GMP operational by the end of 2024.

Download

On eve of CPHI Hanns-Christian Mahler stresses the importance of holistic sterile drug product development

Basel, 23^rd of October 2023: On the eve of CPHI, ten23 health®, a global contract development and manufacturing organization, today announced that CEO Hanns-Christian Mahler will give a webinar stressing the importance of holistic sterile drug product development.  

Download

You missed the webinar? You can rewatch it here

ten23 health announces the successful implementation and certification of the ISO 9001:2015 Quality Management for its Development services in Basel.

Basel, 11^th of September 2023. ten23 health® is happy to announce this implementation. Using ISO 9001 helps ensure that customers get consistent, good-quality products and services.

Download

ten23 health expands sterile manufacturing capacity at its VIVA 1® facility through completion of its first expansion and the introduction of an additional shift

Basel, 4th of September 2023. ten23 health® announces a capacity expansion for the manufacture of sterile drug product at its Visp facility. This will help to meet rapidly increasing customer demand.

Download

ten23 health announces expansion with the launch of quality control services

July 10^th, 2023 - ten23 health® announces the launch of “quality control” (QC) service offerings in Switzerland for release and stability testing of clinical and commercial sterile drug products according to international cGMP standards.

Download

ten23 health and Elio, an AI co-pilot for eco-design, announced today their collaboration to integrate sustainability into process design for parenteral products.

July 3^rd, 2023 - Recognizing the urgent need for sustainable practices across industries, ten23 health and Elio are harnessing the power of artificial intelligence (AI) and big data to drive change and foster environmentally conscious development.

Download

ten23 health publishes its Fairstainability Impact Report 2022 and is delivering good progress on Patients, People and Planet goals

May 30^th,  2023 - ten23 health announces the publication of its fully voluntary Fairness and Sustainability (“Fairstainability”) Impact report 2022, detailing activities and data from last year, as well as recent progress against our Goals, in line with ten23 health’s commitment on Patients, People and Planet.

Download

Non-destructive particle counting - ten23 health and Bionter collaborate to improve testing of particulates in sterile products.

May 2^nd,  2023 - ten23 health and Bionter, a premium supplier of analytical testing technology, announced today their collaboration to advance innovative testing methods of particulate matter.

Download

04/24/2023  

ten23 health publishes its second Fairstainability report

ten23 health’s purpose is collaborating for a healthy life and planet. The company has therefore voluntarily compiled the status, assessment and actions taken towards fairstainability in 2022. Interested in learning more? Click here

Change in branding: from swissfillon to ten23 health

January 9^th, 2023: ten23 health® announces the change in branding of its in Visp, Switzerland based filling operation from swissfillon to ten23 health. This represents a natural progression since the acquisition of swissfillon by ten23 health in October 2021 and is intended to unify the company’s operations under a single brand and to ease client communication and further strengthen the company’s growing global market position. 

You can read more about Manufacturing here: Delivering / Manufacturing Sterile Product

Download

ten23 health celebrates the FDA approval of scPharmaceuticals` large volume subcutaneous product FUROSCIX® (furosemide injection)

FUROSCIX® is the first and only FDA-approved subcutaneous loop diuretic that can be self-administered at-home. ten23 health has supported scPharmaceuticals in the development of FUROSCIX which they expect to commercially launch in Q1 2023.

Download

ten23 health completes the superstructure of their new large-scale sterile production facility in Visp, Switzerland

With the initial phase of construction now complete, ten23 will commence with interior construction and hiring of further team members. The sterile manufacturing plant is well on track to be operational in 2024 for global commercial supplies of injectable drugs. 

Download

ten23 health announces major expansion in Switzerland with two new sterile manufacturing lines

The dedicated 5,000 square meter facility will provide an additional 30+ million units/year of fill and finish capacity. Raw construction is scheduled for completion in summer 2022 – the plant will be operational in 2024 and create more than 100 jobs. 

Download

ten23 health obtains “Pending B Corp” status and joins both the “Swiss Triple Impact Directory” and the “United Nations Global Compact” (UN GC) program  

As of today, ten23 health becomes a “Pending B Corporation”, which means that the company meets the legal accountability requirement for B Corp Certification and takes measures to manage its social and environmental performance

Download

ten23 health collaborates with Klima for a carbon-neutral workforce.

With this cooperation, ten23 health is among the first pharmaceutical service providers to support a carbon-neutral workforce, in line with its pledges for Patients, People and Planet. 

Download

04/19/2022  

ten23 health issues its first Fairstainability report

ten23 health’s purpose is collaborating for a healthy life and planet. The company has therefore voluntarily compiled the status, assessment and actions taken since its launch in August 2021. The report also includes the full-year data of swiss­fillon AG, a ten23 health company, acquired in October 2021. Interested in learning more? Click here 

ten23 health expands its sterile drug product manufacturing site at Visp, Switzerland

Download

Successful launch and strengthening of Board of Directors

Download

Swissfillon, a leader in sterile filling of complex pharmaceuticals, joins ten23 health and enhances the combined company’s integrated offering to its customers

Download

ten23 health is partnering with Seven Clean Seas related to plastic waste

Download

ten23 health is Silver Sponsor of the 2021 PDA The Universe of Pre-filled Syringes and Injection Devices Conference. 

ten23 health proudly sponsors the 2021 PDA Universe of Pre-filled Syringes and Injection Devices, taking place online during

Oct 5 - Oct 6, 2021

Come visit us virtually!

2021 PDA The Universe of Pre-filled Syringes and Injection Devices Program

Launch of ten23 health – opening a new chapter in contract pharmaceutical development and manufacturing services

Download